Playback speed
10 seconds
NSCLC & Targeted Therapy: A Brief Overview and Update in the Metastatic Setting
By
Memorial Sloan Kettering Cancer Center
FEATURING
Michael Hwang
By
Memorial Sloan Kettering Cancer Center
FEATURING
Michael Hwang
632 views
December 13, 2023
Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
Login to view comments.
Click here to Login